13 decide that the optimum medical strategy for a patient at low risk of disease progression, particularly in the adjuvant setting following radical prostatectomy, may be to defer hormonal therapy until signs that the disease is progressing .” Section 5.1 of the SPC also includes a summary of the efficacy results from the EPC study.